PubMed:16682955
Annnotations
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 16682955-0#24#28#gene10818 | 24-28 | gene10818 | denotes | FRS2 |
| 16682955-0#83#86#gene27352 | 83-86 | gene27352 | denotes | MAP |
| 16682955-0#163#168#gene2246 | 163-168 | gene2246 | denotes | FGF-1 |
| 16682955-0#178#194#diseaseC0678222 | 178-194 | diseaseC0678222 | denotes | breast carcinoma |
| 16682955-1#72#89#gene2099 | 274-291 | gene2099 | denotes | estrogen receptor |
| 16682955-1#141#154#diseaseC0006142 | 343-356 | diseaseC0006142 | denotes | breast cancer |
| 16682955-1#141#154#diseaseC0678222 | 343-356 | diseaseC0678222 | denotes | breast cancer |
| 16682955-3#32#37#gene6640 | 720-725 | gene6640 | denotes | SNT-1 |
| 16682955-3#39#44#gene6640 | 727-732 | gene6640 | denotes | SNT-1 |
| 16682955-3#83#99#diseaseC0678222 | 771-787 | diseaseC0678222 | denotes | breast carcinoma |
| 16682955-9#212#217#gene10818 | 2109-2114 | gene10818 | denotes | SNT-1 |
| 16682955-9#212#217#gene6640 | 2109-2114 | gene6640 | denotes | SNT-1 |
| 16682955-9#0#26#gene2246 | 1897-1923 | gene2246 | denotes | Fibroblast growth factor-1 |
| 16682955-9#286#300#diseaseC0006142 | 2183-2197 | diseaseC0006142 | denotes | breast cancers |
| 16682955-9#286#300#diseaseC0006142 | 2183-2197 | diseaseC0006142 | denotes | breast cancers |
| 24#28#gene10818178#194#diseaseC0678222 | 16682955-0#24#28#gene10818 | 16682955-0#178#194#diseaseC0678222 | associated_with | FRS2,breast carcinoma |
| 83#86#gene27352178#194#diseaseC0678222 | 16682955-0#83#86#gene27352 | 16682955-0#178#194#diseaseC0678222 | associated_with | MAP,breast carcinoma |
| 163#168#gene2246178#194#diseaseC0678222 | 16682955-0#163#168#gene2246 | 16682955-0#178#194#diseaseC0678222 | associated_with | FGF-1,breast carcinoma |
| 72#89#gene2099141#154#diseaseC0006142 | 16682955-1#72#89#gene2099 | 16682955-1#141#154#diseaseC0006142 | associated_with | estrogen receptor,breast cancer |
| 72#89#gene2099141#154#diseaseC0678222 | 16682955-1#72#89#gene2099 | 16682955-1#141#154#diseaseC0678222 | associated_with | estrogen receptor,breast cancer |
| 32#37#gene664083#99#diseaseC0678222 | 16682955-3#32#37#gene6640 | 16682955-3#83#99#diseaseC0678222 | associated_with | SNT-1,breast carcinoma |
| 39#44#gene664083#99#diseaseC0678222 | 16682955-3#39#44#gene6640 | 16682955-3#83#99#diseaseC0678222 | associated_with | SNT-1,breast carcinoma |
| 212#217#gene10818286#300#diseaseC0006142 | 16682955-9#212#217#gene10818 | 16682955-9#286#300#diseaseC0006142 | associated_with | SNT-1,breast cancers |
| 212#217#gene10818286#300#diseaseC0006142 | 16682955-9#212#217#gene10818 | 16682955-9#286#300#diseaseC0006142 | associated_with | SNT-1,breast cancers |
| 212#217#gene6640286#300#diseaseC0006142 | 16682955-9#212#217#gene6640 | 16682955-9#286#300#diseaseC0006142 | associated_with | SNT-1,breast cancers |
| 212#217#gene6640286#300#diseaseC0006142 | 16682955-9#212#217#gene6640 | 16682955-9#286#300#diseaseC0006142 | associated_with | SNT-1,breast cancers |
| 0#26#gene2246286#300#diseaseC0006142 | 16682955-9#0#26#gene2246 | 16682955-9#286#300#diseaseC0006142 | associated_with | Fibroblast growth factor-1,breast cancers |
| 0#26#gene2246286#300#diseaseC0006142 | 16682955-9#0#26#gene2246 | 16682955-9#286#300#diseaseC0006142 | associated_with | Fibroblast growth factor-1,breast cancers |
DisGeNet-2017-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T437 | 2109-2114 | gene:10818 | denotes | SNT-1 |
| T438 | 2183-2197 | disease:C0006142 | denotes | breast cancers |
| T2547 | 274-291 | gene:2099 | denotes | estrogen receptor |
| T2548 | 343-356 | disease:C0006142 | denotes | breast cancer |
| R1 | T437 | T438 | associated_with | SNT-1,breast cancers |
| R2 | T437 | T438 | associated_with | SNT-1,breast cancers |
| R1 | T2547 | T2548 | associated_with | estrogen receptor,breast cancer |
| R2 | T2547 | T2548 | associated_with | estrogen receptor,breast cancer |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-201 | Sentence | denotes | Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. |
| TextSentencer_T2 | 202-363 | Sentence | denotes | Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER+) breast cancer cells. |
| TextSentencer_T3 | 364-687 | Sentence | denotes | Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). |
| TextSentencer_T4 | 688-949 | Sentence | denotes | By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER+ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. |
| TextSentencer_T5 | 950-1230 | Sentence | denotes | Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. |
| TextSentencer_T6 | 1231-1375 | Sentence | denotes | SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. |
| TextSentencer_T7 | 1376-1473 | Sentence | denotes | Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. |
| TextSentencer_T8 | 1474-1731 | Sentence | denotes | This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. |
| TextSentencer_T9 | 1732-1896 | Sentence | denotes | Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. |
| TextSentencer_T10 | 1897-2198 | Sentence | denotes | Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers. |
| T1 | 0-201 | Sentence | denotes | Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. |
| T2 | 202-363 | Sentence | denotes | Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER+) breast cancer cells. |
| T3 | 364-687 | Sentence | denotes | Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). |
| T4 | 688-949 | Sentence | denotes | By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER+ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. |
| T5 | 950-1230 | Sentence | denotes | Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. |
| T6 | 1231-1375 | Sentence | denotes | SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. |
| T7 | 1376-1473 | Sentence | denotes | Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. |
| T8 | 1474-1731 | Sentence | denotes | This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. |
| T9 | 1732-1896 | Sentence | denotes | Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. |
| T10 | 1897-2198 | Sentence | denotes | Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers. |
UBERON-AE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 178-184 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
| PD-UBERON-AE-B_T2 | 343-349 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
| PD-UBERON-AE-B_T3 | 771-777 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
| PD-UBERON-AE-B_T4 | 2183-2189 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 178-184 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
| PD-UBERON-AE-B_T2 | 343-349 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
| PD-UBERON-AE-B_T3 | 771-777 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
| PD-UBERON-AE-B_T4 | 2183-2189 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 274-291 | gene:2099 | denotes | estrogen receptor |
| T1 | 343-356 | disease:C0678222 | denotes | breast cancer |
| T2 | 274-291 | gene:2099 | denotes | estrogen receptor |
| T3 | 343-356 | disease:C0006142 | denotes | breast cancer |
| T4 | 727-732 | gene:10818 | denotes | SNT-1 |
| T5 | 771-787 | disease:C0678222 | denotes | breast carcinoma |
| T6 | 720-725 | gene:6640 | denotes | SNT-1 |
| T7 | 771-787 | disease:C0678222 | denotes | breast carcinoma |
| T8 | 727-732 | gene:10818 | denotes | SNT-1 |
| T9 | 771-787 | disease:C0006142 | denotes | breast carcinoma |
| T10 | 720-725 | gene:6640 | denotes | SNT-1 |
| T11 | 771-787 | disease:C0006142 | denotes | breast carcinoma |
| T12 | 727-732 | gene:6640 | denotes | SNT-1 |
| T13 | 771-787 | disease:C0006142 | denotes | breast carcinoma |
| T14 | 727-732 | gene:6640 | denotes | SNT-1 |
| T15 | 771-787 | disease:C0678222 | denotes | breast carcinoma |
| T16 | 720-725 | gene:10818 | denotes | SNT-1 |
| T17 | 771-787 | disease:C0678222 | denotes | breast carcinoma |
| T18 | 720-725 | gene:10818 | denotes | SNT-1 |
| T19 | 771-787 | disease:C0006142 | denotes | breast carcinoma |
| R1 | T0 | T1 | associated_with | estrogen receptor,breast cancer |
| R2 | T2 | T3 | associated_with | estrogen receptor,breast cancer |
| R3 | T4 | T5 | associated_with | SNT-1,breast carcinoma |
| R4 | T6 | T7 | associated_with | SNT-1,breast carcinoma |
| R5 | T8 | T9 | associated_with | SNT-1,breast carcinoma |
| R6 | T10 | T11 | associated_with | SNT-1,breast carcinoma |
| R7 | T12 | T13 | associated_with | SNT-1,breast carcinoma |
| R8 | T14 | T15 | associated_with | SNT-1,breast carcinoma |
| R9 | T16 | T17 | associated_with | SNT-1,breast carcinoma |
| R10 | T18 | T19 | associated_with | SNT-1,breast carcinoma |